手法を比較
選択した手法を並べて確認できます。異なる行はハイライト表示されます。
| Caco-2細胞透過性アッセイ× | リポソーム薬物送達× | |
|---|---|---|
| 分野 | 薬理学 | 薬理学 |
| 系統 | Process / pipeline | Process / pipeline |
| 提唱年≠ | 1989 | 1965 |
| 提唱者≠ | Ingrid Hidalgo | Alec Bangham |
| 種類≠ | absorption screening | formulation technology |
| 原典≠ | Hidalgo, I. J., Raub, T. J., & Borchardt, R. T. (1989). Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology, 96(3), 736-749. DOI ↗ | Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965). Diffusion of univalent ions across the lamellae of swollen phospholipid films and the determination of membrane potential. Journal of Molecular Biology, 13(1), 238-252. DOI ↗ |
| 別名 | Caco-2 assay, intestinal permeability, ADME screening | liposomal formulation, vesicular delivery, lipid nanoparticles |
| 関連 | 3 | 3 |
| 概要≠ | The Caco-2 assay is an in vitro model system using human colon carcinoma cell monolayers to screen drug intestinal permeability. Developed by Hidalgo and colleagues in 1989, Caco-2 cells differentiate into an epithelial barrier resembling intestinal mucosa, enabling rapid assessment of drug absorption potential and identification of transporter-mediated transport. | Liposomal encapsulation is a formulation technique using lipid bilayer vesicles (liposomes) to enclose drugs, improving bioavailability, reducing toxicity, and enabling targeted delivery. Developed by Alec Bangham in 1965, liposomes are now standard in pharmaceutical development, with several FDA-approved liposomal drugs on the market. |
| ScholarGateデータセット ↗ |
|
|